Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bergler-Klein, J; Rainer, PP; Wallner, M; Zaruba, MM; Dörler, J; Böhmer, A; Buchacher, T; Frey, M; Adlbrecht, C; Bartsch, R; Gyöngyösi, M; Fürst, UM.
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Wien Klin Wochenschr. 2022; 134(17-18):654-674
Doi: 10.1007/s00508-022-02031-0
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Rainer Peter
- Wallner Markus
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Survival in cancer is continuously improving due to evolving oncological treatment. Therefore, cardiovascular short-term and long-term side effects gain crucial importance for overall outcome. Cardiotoxicity not only presents as heart failure, but also as treatment-resistant hypertension, acute coronary ischemia with plaque rupture or vasospasm, thromboembolism, arrhythmia, pulmonary hypertension, diastolic dysfunction, acute myocarditis and others. Recent recommendations have proposed baseline cardiac risk assessment and surveillance strategies. Major challenges are the availability of monitoring and imaging resources, including echocardiography with speckle tracking longitudinal strain (GLS), serum biomarkers such as natriuretic peptides (NT-proBNP) and highly sensitive cardiac troponins. This Austrian consensus encompasses cardiotoxicity occurrence in frequent antiproliferative cancer drugs, radiotherapy, immune checkpoint inhibitors and cardiac follow-up considerations in cancer survivors in the context of the Austrian healthcare setting. It is important to optimize cardiovascular risk factors and pre-existing cardiac diseases without delaying oncological treatment. If left ventricular ejection fraction (LVEF) deteriorates during cancer treatment (from >10% to <50%), or myocardial strain decreases (>15% change in GLS), early initiation of cardioprotective therapies (angiotensin-converting enzyme inhibitors, angiotensin or beta receptor blockers) is recommended, and LVEF should be reassessed before discontinuation. Lower LVEF cut-offs were recently shown to be feasible in breast cancer patients to enable optimal anticancer treatment. Interdisciplinary cardio-oncology cooperation is pivotal for optimal management of cancer patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiotensin-Converting Enzyme Inhibitors - therapeutic use
- Angiotensins - pharmacology, therapeutic use
- Antineoplastic Agents - adverse effects
- Austria - administration & dosage
- Biomarkers - administration & dosage
- Breast Neoplasms - administration & dosage
- Cardiology - administration & dosage
- Cardiotoxicity - diagnosis, drug therapy, etiology
- Female - administration & dosage
- Heart Failure - chemically induced, diagnosis, therapy
- Humans - administration & dosage
- Immune Checkpoint Inhibitors - administration & dosage
- Natriuretic Peptides - pharmacology, therapeutic use
- Stroke Volume - administration & dosage
- Troponin - administration & dosage
- Ventricular Function, Left - administration & dosage
- Find related publications in this database (Keywords)
- Heart failure
- Chemotherapy
- Immune checkpoint inhibitors
- Radiation therapy
- Targeted therapy